GlobalX China Semiconductor ETF (03191.HK) Fell 3.25% to 89.780 HKD
Newtimespace News, as of 15:59 on May 21, GlobalX China Semiconductor ETF (03191.HK) was quoted at HKD 89.780, down 3.25%. The ETF opened at HKD 93.260, with a high of HKD 97.220 and a low of HKD 89.400. The latest Net Asset Value (NAV) per unit is HKD 92.439, with a premium rate of 0.39%. The asset size is approximately HKD 2.804 billion.
GlobalX China Semiconductor ETF (03191.HK) is a passive ETF managed by Mirae Asset Global Investments (Hong Kong) Limited. It aims to provide, before fees and expenses, investment returns that closely correlate with the performance of the FactSet China Semiconductor Index. The FactSet China Semiconductor Index is compiled and published by the global financial data provider FactSet. It is a net total return index denominated in Renminbi (RMB). The index aims to comprehensively reflect the overall performance of companies across the entire Chinese semiconductor industry chain, covering leading enterprises in areas such as integrated circuit design, manufacturing (foundry), packaging and testing, and semiconductor production equipment.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment